

UniSpend Anhydrous®

Your resource in case of no known stability



Your resource in case of no known stability

In need for a palatable, easy to compound oral liquid for your patient, but lacking stability data? UniSpend Anhydrous® might be just what you are looking for.

Aqueous stability is not known for all Active Pharmaceutical Ingredient (APIs) in the market and many more APIs are known to be unstable in the presence of water. Without available stability information, these APIs can be challenging for the pharmacist. UniSpend Anhydrous® is a water-free, easy to use, plant-based oral suspension vehicle based on medium chain triglycerides that are extremely resistant to oxidation. Based on USP <795> a beyond-use-date (BUD) of up to 90 days can be given, in case the aqueous stability is unknown.¹





Designed for vulnerable patients

Keeping vulnerable patients in mind, UniSpend Anhydrous® is without preservative, dyes or BHT. All ingredients used in UniSpend Anhydrous® are FDA GRAS listed.² UniSpend Anhydrous® is very suitable for patients with common food allergies as it contains no corn, soy, dairy, nuts, gluten or eggs. The medium chain triglycerides make it ideal in case of ketogenic diets in drug-resistant epilepsy, as shown in the literature.³

Optimal palatability

UniSpend Anhydrous® comes in a sweetened and unsweetened version. UniSpend Anhydrous® sweetened is naturally sweetened with stevia and fortified with a natural bitterness masking agent for optimal palatability. UniSpend Anhydrous® can easily be flavored according to your patient's needs using water-soluble and oilmiscible flavors.

Example formulations⁴

Doxycycline 50 mg/mL in UniSpend Anhydrous® Sweetened

Hydrocortisone 2 mg/mL in UniSpend Anhydrous® Unsweetened Methimazole 5 mg/mL in UniSpend Anhydrous® Sweetened

Calcitriol 10 nanogram/0.1 mL in UniSpend Anhydrous® Unsweetened Progesterone 20 mg/0.2 mL in UniSpend Anhydrous® Sweetened

Azathioprine 50 mg/mL in UniSpend Anhydrous® Unsweetened

Formulation references

- 1. USP <795> Pharmaceutical compounding nonsterile preparations
- 2. www.accessdata.fda.gov/scripts/fdcc/?set=SCOGS
- 3. Liu YM, Wang HS. Medium-chain triglyceride ketogenic diet, an effective treatment for drug-resistant epilepsy and a comparison with other ketogenic diets. Biomed J. 2013;36:9-15.
- 4. www.fagronacademy.us/facts/ accessed April 2019